Mycenax Biotech Inc. (TPEX:4726)
Taiwan · Delayed Price · Currency is TWD 24.30
+0.30 (1.25%)
Aug 19, 2026, 1:30 PM CST
Mycenax Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 815.87 | 740.24 | 683.92 | 652.62 | 732.28 | 774.27 | |
Revenue Growth | 12.16% | 8.23% | 4.80% | -10.88% | -5.42% | 16.37% |
Cost of Revenue | 953.55 | 921.65 | 925.28 | 1,028 | 845.95 | 636.66 |
Gross Profit | -137.68 | -181.41 | -241.36 | -375.19 | -113.67 | 137.61 |
Selling, General & Admin | 152.59 | 148.07 | 141.94 | 152.23 | 156.16 | 133.96 |
Research & Development | 64.28 | 75.91 | 78.19 | 75.81 | 144 | 96.13 |
Operating Expenses | 218.65 | 222.43 | 220.18 | 226.91 | 331.32 | 222.94 |
Operating Income | -356.33 | -403.84 | -461.54 | -602.1 | -445 | -85.33 |
Interest Expense | -32.58 | -29.47 | -26.16 | -23.46 | -15.42 | -1.17 |
Interest & Investment Income | 2.51 | 3.12 | 8.53 | 17.66 | 3.8 | 0.31 |
Earnings From Equity Investments | -21.13 | -21.13 | -12.94 | -8.7 | -0.76 | - |
Currency Exchange Gain (Loss) | 21.18 | -10.01 | 14.58 | 3.35 | 13.29 | -1.35 |
Other Non Operating Income (Expenses) | -9.58 | 1 | -3.9 | 0.75 | 0.21 | -0.11 |
EBT Excluding Unusual Items | -395.94 | -460.33 | -481.43 | -612.5 | -443.87 | -87.65 |
Gain (Loss) on Sale of Assets | 0.22 | 0.22 | - | - | -20.11 | 0.13 |
Other Unusual Items | - | - | - | -71.48 | 1.13 | - |
Pretax Income | -389.72 | -454.11 | -469.59 | -683.98 | -462.84 | -87.52 |
Income Tax Expense | -7.81 | -5.48 | -2.46 | -1.13 | -9.21 | 2.34 |
Net Income | -381.91 | -448.63 | -467.13 | -682.85 | -453.63 | -89.86 |
Net Income to Common | -381.91 | -448.63 | -467.13 | -682.85 | -453.63 | -89.86 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 208 | 207 | 206 | 206 | 165 | 148 |
Shares Outstanding (Diluted) | 208 | 207 | 206 | 206 | 165 | 148 |
Shares Change | 0.75% | 0.55% | 0.23% | 24.31% | 11.35% | 15.36% |
EPS (Basic) | -1.84 | -2.17 | -2.27 | -3.32 | -2.74 | -0.61 |
EPS (Diluted) | -1.84 | -2.17 | -2.27 | -3.32 | -2.74 | -0.61 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -13.51 | -115.78 | -522.11 | -426.81 | -777.12 | -1,244 |
Free Cash Flow Per Share | -0.07 | -0.56 | -2.54 | -2.08 | -4.70 | -8.38 |
Gross Margin | -16.88% | -24.51% | -35.29% | -57.49% | -15.52% | 17.77% |
Operating Margin | -43.68% | -54.55% | -67.48% | -92.26% | -60.77% | -11.02% |
Profit Margin | -46.81% | -60.61% | -68.30% | -104.63% | -61.95% | -11.61% |
Free Cash Flow Margin | -1.65% | -15.64% | -76.34% | -65.40% | -106.12% | -160.71% |
EBITDA | -96.56 | -168.6 | -206.91 | -338.27 | -219.7 | 44.33 |
EBITDA Margin | -11.83% | -22.78% | -30.25% | -51.83% | -30.00% | 5.73% |
D&A For EBITDA | 259.77 | 235.24 | 254.63 | 263.83 | 225.3 | 129.66 |
EBIT | -356.33 | -403.84 | -461.54 | -602.1 | -445 | -85.33 |
EBIT Margin | -43.68% | -54.55% | -67.48% | -92.26% | -60.77% | -11.02% |